Physician profile
Marilyn Hepperle
NPI 1215086111
$4,097.85
in general payments reported to CMS, 2019-2025
35 companies · $518 in 2025
The $518 reported for 2025 was more than what 79% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $896 · 2020: $506 · 2021: $543 · 2022: $511 · 2023: $713 · 2024: $411 · 2025: $518.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,634 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,633.59 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $571.83 | 2021-2025 | |
| Amgen INC. | $475.11 | 2019-2025 | Krystexxa, Repatha, Otezla |
| Lilly USA, LLC | $427.60 | 2019-2023 | Emgality |
| Glaxosmithkline, LLC. | $393.05 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $350.35 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $278.24 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $201.28 | 2019-2025 | Xifaxan |
| Teva Pharmaceuticals USA, INC. | $186.32 | 2019-2023 | Austedo, Austedo Xr |
| Novo Nordisk INC | $169.84 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Allergan, INC. | $121.48 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $81.76 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.44 | 2019-2021 | |
| Eisai INC. | $63.83 | 2020-2022 | |
| Mylan Specialty L.P. | $59.31 | 2019-2022 | |
| Dexcom, INC. | $58.50 | 2023-2025 | Dexcom G6 Transmitter |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marilyn Hepperle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.